Abstract

Glucagon, the polypeptide humoral substance produced mainly by the alpha cells of the pancreas, is generally considered as a metabolic hormone. Its influence on carbohydrate metabolism has been widely studied and is fairly well known. In addition to the glycogenolytic action, glucagon has also been found to have an inhibitory effect on gastrointestinal motility1-3and gastric acid secretion.4,5By which mechanisms these actions are produced by glucagon and if they are of any physiological significance is not known. The effect of glucagon on the cardiovascular system has been subject to much less study. In 1959, Shoemaker et al,6using sulfobromophthalein (Bromsulphalein [BSP]) methods, studied the effect of glucagon on hepatic blood flow in dogs. They found an increase of blood flow which coincided with the serum glucose increase. In 1962, Merrill et al7reported the effect of glucagon on the superior mesenteric vascular bed. In their

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call